Quick Answer
Dyne Therapeutics, Inc. reported Net Income of -$446.21 million for fiscal year 2025.
Dyne Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$446.21M -40.6% |
-$317.42M -34.5% |
-$235.94M -40.4% |
-$168.10M -12.6% |
-$149.29M -151.2% |
-$59.44M -300.0% |
| Diluted EPS | -$3.47 -3.0% |
-$3.37 +14.7% |
-$3.95 -22.3% |
-$3.23 -10.2% |
-$2.93 | — |
| Total Assets | $1.19B +71.7% |
$691.23M +318.7% |
$165.08M -46.1% |
$306.32M -28.0% |
$425.66M +20.5% |
$353.33M +2049.8% |
| Cash and Equivalents | $893.37M +105.2% |
$435.45M +258.0% |
$121.63M -29.3% |
$172.15M -14.3% |
$200.82M -33.2% |
$300.85M +1956.1% |
| Long-Term Debt | $148.92M | $0.00 | — | — | — | — |
| Stockholders Equity | $972.13M +54.3% |
$629.84M +589.9% |
$91.29M -63.8% |
$252.36M -31.5% |
$368.20M +7.5% |
$342.37M +2339.2% |
| R&D Expense | $398.33M +41.6% |
$281.41M +33.5% |
$210.76M +47.6% |
$142.76M +17.7% |
$121.31M +168.4% |
$45.20M +309.4% |
| Operating Income | -$468.18M -36.1% |
-$343.89M -42.0% |
-$242.16M -41.6% |
-$170.96M -14.0% |
-$150.03M -155.8% |
-$58.65M -324.2% |
| Shares Outstanding | 164.95M +61.2% |
102.32M +66.5% |
61.47M +10.5% |
55.64M +7.9% |
51.57M +14.4% |
45.08M +1642.7% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$108.04M | -11.2% | +2.5% |
| Diluted EPS | September 30, 2025 | -$0.76 | +20.8% | +21.6% |
| Total Assets | September 30, 2025 | $867.06M | +12.8% | +18.9% |
| Cash and Equivalents | September 30, 2025 | $573.61M | +7.8% | +18.3% |
| Long-Term Debt | September 30, 2025 | $99.15M | — | +0.3% |
| Stockholders Equity | September 30, 2025 | $691.78M | -1.9% | +21.1% |
| R&D Expense | September 30, 2025 | $97.22M | +4.8% | -2.0% |
| Operating Income | September 30, 2025 | -$113.89M | -7.9% | +1.6% |
| Shares Outstanding | September 30, 2025 | 142.61M | +40.2% | +24.7% |
- Dyne Therapeutics, Inc. reported Net Income of -$446.21 million for fiscal year 2025.
- Dyne Therapeutics, Inc. showed a decrease of -40.6% in Net Income compared to the prior fiscal year.
- Dyne Therapeutics, Inc. reported Diluted EPS of $3.47 per share (loss) for fiscal year 2025.
- Dyne Therapeutics, Inc. showed a decrease of -3.0% in Diluted EPS compared to the prior fiscal year.
- Dyne Therapeutics, Inc. reported Total Assets of $1.19 billion for fiscal year 2025.
- Dyne Therapeutics, Inc. showed an increase of +71.7% in Total Assets compared to the prior fiscal year.
- Dyne Therapeutics, Inc. reported Cash and Equivalents of $893.37 million for fiscal year 2025.
- Dyne Therapeutics, Inc. showed an increase of +105.2% in Cash and Equivalents compared to the prior fiscal year.
- Dyne Therapeutics, Inc. reported Long-Term Debt of $148.92 million for fiscal year 2025.
- Dyne Therapeutics, Inc. reported Stockholders Equity of $972.13 million for fiscal year 2025.
- Dyne Therapeutics, Inc. showed an increase of +54.3% in Stockholders Equity compared to the prior fiscal year.
- Dyne Therapeutics, Inc. reported R&D Expense of $398.33 million for fiscal year 2025.
- Dyne Therapeutics, Inc. showed an increase of +41.6% in R&D Expense compared to the prior fiscal year.
- Dyne Therapeutics, Inc. reported Operating Income of -$468.18 million for fiscal year 2025.
- Dyne Therapeutics, Inc. showed a decrease of -36.1% in Operating Income compared to the prior fiscal year.
- Dyne Therapeutics, Inc. reported Shares Outstanding of 164.95 million shares for fiscal year 2025.
- Dyne Therapeutics, Inc. showed an increase of +61.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: